OptimizeRx — Third Quarter 2026 Earnings Summary

OptimizeRx reported third-quarter 2026 revenue of $21.6 million, a 17% decrease from the prior year, while achieving a net income of $1.2 million and adjusted EBITDA of $6.3 million. The company updated its full-year 2026 revenue guidance to a range of $87 million to $93 million, though adjusted EBITDA guidance remains unchanged at $21 million to $25 million. Since June 30, 2026, OptimizeRx repaid $9.3 million in debt principal, reducing its outstanding principal balance to $10.4 million. Management cited margin expansion and cost management as drivers for the 23% year-over-year increase in adjusted EBITDA despite the revenue decline.